Skip to content

Off-the-Shelf Immunotherapy for Solid Tumors

Engineered viral platforms that activate the immune system to recognize and destroy cancer cells.

Powerful Outcomes, Preserved Quality of Life

For too long, fighting cancer has meant harsh treatments and diminished quality of life. We believe in a different path.

Our mission is simple: to extend and improve lives through cancer immunotherapy innovation, without the toxicity of traditional approaches.

Real Results for Real Patients 

30% Improvement in disease-free survival in prostate cancer

Phase 3 data for our lead therapy,  aglatimagene besadenovec, is demonstrating meaningful outcomes for prostate cancer.

  • Eight out of ten patients achieved complete pathological response at two years —significantly higher than standard radiation alone.
  • Aglatimagene treatment was well tolerated with minimal serious side effects, preserving quality of life during treatment.
  • FDA Fast Track and RMAT Designation granted based on results from 745 patients enrolled under Special Protocol Assessment.
30% Improvement in disease-free survival in prostate cancer

Engineered Viruses. Empowered Immune Systems.

Candel has established two off-the-shelf clinical-stage investigational viral immunotherapies designed to deliver meaningful and durable clinical benefit through individualized immune activation based on novel, genetically modified viral constructs.

HSV TK gene

aglatimagene besodenovec (aglatimagene or CAN-2409)

Gene Therapy Vector with Systemic Impact

HSV TK gene (1)

Aglatimagene is an adenoviral gene construct encoding HSV-thymidine kinase, injected directly into the tumor. When combined with FDA-approved oral prodrugs, it triggers immunogenic cell death and creates optimal conditions for CD8+ T cell–mediated anti-tumor immunity. 

Nestin promoter: ICP34.5

linoserpaturev  or CAN-3110

Oncolytic Virus with Tumor Specificity

Nestin promoter: ICP34.5

Linoserpaturev is a replication-competent HSV engineered for selective killing of cancer cells while sparing healthy tissue. Controlled by the Nestin promoter, it targets high-grade glioma cells with precision. This tumor-specific approach enables multiple dosing without dose-limiting toxicity.

Find Your Path

Whether you’re seeking treatment options, clinical evidence, or investment opportunities, we’re here to guide you.

For Patients

For Patients 

Your Journey Starts Here

Hope backed by science. Explore active clinical trials designed to improve survival while maintaining quality of life.

Learn More
For Providers

For Providers 

Evidence-Based 
Innovation

Evidence to inform your practice. Review Phase 3 data, safety profiles, and mechanism of action for viral immunotherapy across solid tumors.

Investigator Resources
For Investors

For Investors 

Clinical Progress, 
Commercial Potential

Clinical validation with commercial potential. Review Phase 3 data, BLA readiness, and our multimodal platform approach.

Investor Relations